Allergan acquires EarFold ear implant assets

Allergan (NYSE: AGN) said today it agreed to acquire Northwood Medical’s EarFold implant technology designed to correct prominent ears, with or without asymmetry, in patients 7 years or older. The device from London-based Northwood is a small implantable strip of nitinol metal alloy that is inserted under the skin and grips ear cartilage, enhancing or creating the shape of the anti-helical fold and reducing ear prominence, the company said. “EarFold technology adds another innovative product to our medical aesthetics product portfolio, especially for the plastic surgeons we serve today, and has the potential to expand the number of patients interested in corrective surgery as it provides an alternative treatment that may appeal to those who have been reluctant to undergo traditional surgical procedures. Many of Allergan’s plastic surgery customers currently perform otoplasty procedures, emphasizing our commitment to serving the unmet needs and practice of plastic surgery,” Allergan international brands prez Paul Navarre said in a press release. The EarFold device won CE Mark approval in the European Union in April this year, Allergan said. Upon the closure of the acquisition, Allergan intends to commercialize the product “widely across Europe,” and will continue to explore regulatory pathways and requirements to commercialize the device in other countries, including the U.S. Also following closure of the deal, Allergan will “establ...
Source: Mass Device - Category: Medical Equipment Authors: Tags: Business/Financial News Cosmetic/Aesthetic Mergers & Acquisitions Allergan Inc. Source Type: news